使用Ch1VPP（一种低毒药物组合）治疗霍奇金病的三年经验。
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.
作者信息
Kaye S B, Juttner C A, Smith I E, Barrett A, Austin D E, Peckham M J, McElwain T J
出版信息
Br J Cancer. 1979 Feb;39(2):168-74. doi: 10.1038/bjc.1979.27.
In 3 years, 118 patients with Hodgkin's disease have completed chemotherapy with chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). The complete remission rates were 90% for 29 patients previously treated with radiotherapy, 67% for 73 patients previously untreated and 44% for 16 patients with prior chemotherapy. The 3-year survival rates for the first 70 patients in the series were 83% for previously irradiated patients, 84% for previously untreated patients and 67% for those with prior chemotherapy. Forty-seven previously untreated or previously irradiated patients in this group achieved complete remission. The 3-year disease-free survival rates for these patients were 71% and 67% respectively. This regimen gives complete remission and survival rates comparable with results obtained with combinations including nitrogen mustard, while producing fewer side-effects.
3年间，118例霍奇金病患者完成了苯丁酸氮芥、长春花碱、丙卡巴肼和泼尼松（Ch1VPP）化疗。29例先前接受过放疗的患者完全缓解率为90%，73例先前未接受过治疗的患者为67%，16例先前接受过化疗的患者为44%。该系列中前70例患者的3年生存率，先前接受过放疗的患者为83%，先前未接受过治疗的患者为84%，先前接受过化疗的患者为67%。该组中47例先前未接受过治疗或先前接受过放疗的患者实现了完全缓解。这些患者 的3年无病生存率分别为71%和67%。该方案产生的完全缓解率和生存率与包括氮芥在内的联合方案相当，同时副作用更少。
Zotero 插件